F. Christopher Zusi

1.3k total citations
19 papers, 1.0k citations indexed

About

F. Christopher Zusi is a scholar working on Molecular Biology, Organic Chemistry and Cancer Research. According to data from OpenAlex, F. Christopher Zusi has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Organic Chemistry and 6 papers in Cancer Research. Recurrent topics in F. Christopher Zusi's work include Retinoids in leukemia and cellular processes (6 papers), NF-κB Signaling Pathways (6 papers) and Immune Response and Inflammation (3 papers). F. Christopher Zusi is often cited by papers focused on Retinoids in leukemia and cellular processes (6 papers), NF-κB Signaling Pathways (6 papers) and Immune Response and Inflammation (3 papers). F. Christopher Zusi collaborates with scholars based in United States, Germany and Malaysia. F. Christopher Zusi's co-authors include James R. Burke, Yuping Qiu, Kim W. McIntyre, Mark A. Pattoli, John F. MacMaster, Kurt R. Gregor, Patrick Brassil, Xiaoxia Yang, Wendy Clarke and Joann Strnad and has published in prestigious journals such as Journal of Biological Chemistry, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

F. Christopher Zusi

18 papers receiving 1.0k citations

Peers

F. Christopher Zusi
Marie Chabot‐Fletcher United States
Shrikanth A.G. Reddy United States
Matthew J. Strouch United States
Uttam Pati India
Shengyou Liao China
Donghwa Kim South Korea
Jui-Wen Huang Taiwan
Nicholas Brown United Kingdom
M Oshimura Japan
Ki Beom Bae South Korea
Marie Chabot‐Fletcher United States
F. Christopher Zusi
Citations per year, relative to F. Christopher Zusi F. Christopher Zusi (= 1×) peers Marie Chabot‐Fletcher

Countries citing papers authored by F. Christopher Zusi

Since Specialization
Citations

This map shows the geographic impact of F. Christopher Zusi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Christopher Zusi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Christopher Zusi more than expected).

Fields of papers citing papers by F. Christopher Zusi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Christopher Zusi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Christopher Zusi. The network helps show where F. Christopher Zusi may publish in the future.

Co-authorship network of co-authors of F. Christopher Zusi

This figure shows the co-authorship network connecting the top 25 collaborators of F. Christopher Zusi. A scholar is included among the top collaborators of F. Christopher Zusi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Christopher Zusi. F. Christopher Zusi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Cook, James A., F. Christopher Zusi, Matthew D. Hill, et al.. (2017). Design and synthesis of a novel series of (1′S,2R,4′S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor. Bioorganic & Medicinal Chemistry Letters. 27(22). 5002–5005. 3 indexed citations
2.
King, Dalton, Ivar M. McDonald, James A. Cook, et al.. (2017). Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR. Bioorganic & Medicinal Chemistry Letters. 27(5). 1261–1266. 7 indexed citations
3.
McDonald, Ivar M., Robert Mate, F. Christopher Zusi, et al.. (2013). Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists. Bioorganic & Medicinal Chemistry Letters. 23(6). 1684–1688. 16 indexed citations
4.
Beaulieu, Françis, Carl Ouellet, Edward H. Ruediger, et al.. (2006). Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(5). 1233–1237. 45 indexed citations
5.
Vivat‐Hannah, Valérie & F. Christopher Zusi. (2005). Retinoids as Therapeutic Agents: Today and Tomorrow. Mini-Reviews in Medicinal Chemistry. 5(8). 755–760. 18 indexed citations
6.
Thompson, Lorin A., Joanne J. Bronson, & F. Christopher Zusi. (2005). Progress in the Discovery of BACE Inhibitors. Current Pharmaceutical Design. 11(26). 3383–3404. 40 indexed citations
7.
Postelnek, Jennifer, Vojkan Susulic, Kim W. McIntyre, et al.. (2004). A HIGHLY SELECTIVE INHIBITOR OF IκB KINASE, BMS-345541, AUGMENTS GRAFT SURVIVAL MEDIATED BY SUBOPTIMAL IMMUNOSUPPRESSION IN A MURINE MODEL OF CARDIAC GRAFT REJECTION. Transplantation. 77(7). 1090–1094. 20 indexed citations
8.
Germain, Pierre, Sabrina Kammerer, Efrén Pérez‐Santín, et al.. (2004). Rational design of RAR‐selective ligands revealed by RARβ crystal stucture. EMBO Reports. 5(9). 877–882. 75 indexed citations
9.
Belema, Makonen, Van N. Nguyen, & F. Christopher Zusi. (2004). Synthesis of 1,1-diarylethylenes from an α-stannyl β-silylstyrene. Tetrahedron Letters. 45(8). 1693–1697. 19 indexed citations
10.
MacMaster, John F., Donna M. Dambach, Yuping Qiu, et al.. (2003). An inhibitor of I?B kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflammation Research. 52(12). 508–511. 46 indexed citations
11.
Burke, James R., Mark A. Pattoli, Kurt R. Gregor, et al.. (2003). BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice. Journal of Biological Chemistry. 278(3). 1450–1456. 439 indexed citations
12.
McIntyre, Kim W., David J. Shuster, Kathleen M. Gillooly, et al.. (2003). A highly selective inhibitor of IκB kinase, BMS‐345541, blocks both joint inflammation and destruction in collagen‐induced arthritis in mice. Arthritis & Rheumatism. 48(9). 2652–2659. 185 indexed citations
13.
Zusi, F. Christopher, Matthew V. Lorenzi, & Valérie Vivat‐Hannah. (2002). Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discovery Today. 7(23). 1165–1174. 59 indexed citations
14.
Vivat‐Hannah, Valérie, Jean‐Paul Daris, F. Christopher Zusi, et al.. (2001). Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel).. PubMed. 61(24). 8703–11. 26 indexed citations
15.
Burke, James R., Mark R. Witmer, F. Christopher Zusi, et al.. (1999). Competitive, Reversible Inhibition of Cytosolic Phospholipase A2 at the Lipid-Water Interface by Choline Derivatives That Partially Partition into the Phospholipid Bilayer. Journal of Biological Chemistry. 274(27). 18864–18871. 4 indexed citations
16.
Lewin, Anita H., et al.. (1994). Evaluation of Retinoids as Therapeutic Agents in Dermatology. Pharmaceutical Research. 11(2). 192–200. 15 indexed citations
17.
Lewin, Anita H., et al.. (1994). The Requirement for a Retinoic Acid Lactone of 11-cis, 13-cis-Stereochemistry for Topical Dermatologic Activity. Pharmaceutical Research. 11(7). 1065–1067. 1 indexed citations
18.
Tramposch, Kenneth M., et al.. (1990). Biochemical and pharmacological properties of a new topical anti-inflammatory compound, 9-phenylnonanohydroxamic acid (BMY 30094). Inflammation Research. 30(3-4). 443–450. 8 indexed citations
19.
Zusi, F. Christopher, et al.. (1979). Frozen Conformers of Clotrimazole: Reaction of Imidazole with 1-chloro-9-hydroxy-9-phenylxanthene. Journal of Pharmaceutical Sciences. 68(11). 1453–1454. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie Chabot‐Fletcher Breakdown of academic impact, for papers by Shrikanth A.G. Reddy Breakdown of academic impact, for papers by Matthew J. Strouch Breakdown of academic impact, for papers by Uttam Pati Breakdown of academic impact, for papers by Shengyou Liao Breakdown of academic impact, for papers by Donghwa Kim Breakdown of academic impact, for papers by Jui-Wen Huang Breakdown of academic impact, for papers by Nicholas Brown Breakdown of academic impact, for papers by M Oshimura Breakdown of academic impact, for papers by Ki Beom Bae
Rankless by CCL
2026